ScripThroughout 2024 and against persistent financial headwinds, novice and returning sole Chinese company sponsors of clinical trials initiated a total of seven new global Phase III programs that included
ScripInnovent Biologics, Inc. and GenFleet Therapeutics on 21 August scored China’s first approval for a KRAS G12C inhibitor, the co-developed Dupert (fulzerasib), winning a head start over foreign and
ScripWho: Merck & Co./C4 Therapeutics What: Merck will call on protein degradation specialist C4 to discover degrader molecules against an unspecified cancer target for use in degrader-antibody conjugat
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daewoong, HanAll Co-Invest In Vinc